Rethinking Clinical Trials

FEBRUARY 20, 2024

Due to the lack of evidence, indications for red blood cell transfusion in patients with MI are controversial. The MINT trial investigators looked at 30-day mortality and several outcomes including MI, heart failure, stroke, bleeding, infection, and clot. There were 3 primary limitations of the MINT trial.

Trials 130

Trials Clinical Trials Clinical Trials Medicine 130

Rethinking Clinical Trials

APRIL 18, 2023

There are many hypothesized causes that may co-exist in the same patient, such as persistent virus or antigens, reactivation of other viruses, uncontrolled immune responses, damage to a wide range of organs and tissues, and injury to blood vessels and abnormal blood clotting.

Clinical Trials 219

Clinical Trials Clinical Trials Trials Immune Response 219

Pharmaceutical Technology

JUNE 21, 2023

The high price tag may be hard to defend , but with lifetime treatment costs for haemophilia B reaching as high as $23m for some, the single-dose treatment could prove far more cost-effective. This protein helps to form blood clots and stop bleeding, with haemophilia B arising when the body is partially or completely unable to produce it.

Gene Therapy 246

Gene Therapy Gene Sales Protein 246

Pharmaceutical Technology

JANUARY 27, 2023

On January 18, Sanofi launched a new warranty program for its rare blood disorder drug Cablivi (caplacizumab), which tackles value-based agreements in a slightly different way. Cablivi stops platelets from clumping together, which prevents small clots, and can be used along with other drugs that suppress the immune system.

Manufacturing 130

Manufacturing Drugs Research Analyst FDA Approval 130

pharmaphorum

AUGUST 26, 2022

The US biotech claimed conditional marketing approval from the European Commission for Roctavian (valoctocogene roxaparvovec) as a treatment for adults with severe haemophilia A, who don’t have a history of developing the antibodies that inhibit the activity of blood-clotting protein Factor VIII. million spread over five years.

Gene Therapy 110

Gene Therapy Gene Antibody Marketing 110

XTalks

NOVEMBER 24, 2022

In a pivotal approval, the US Food and Drug Administration (FDA) has given the nod to a new gene therapy called Hemgenix (etranacogene dezaparvovecfor) for the treatment of adults with the genetic blood disorder hemophilia B (congenital Factor IX deficiency). With a list price of $3.5 Hemophilia B primarily affects men.

Gene Therapy 52

Gene Therapy Gene FDA Approval Genetics 52